바로가기
메인메뉴로 바로가기
콘텐츠 바로가기
하단메뉴로 바로가기
패밀리사이트 바로가기


소속

  • 내과학교실, 종양내과

보직

  • 연세암병원 종양내과장

직위

  • 교수

연구실 위치

전화/팩스

  • 02-2228-8135 / 02-393-3652

학력사항

  • 연세대학교 의과대학 학사(1993)
    연세대학교 의과대학 석사(2003)
    연세대학교 의과대학 박사(2008)

교육 및 연구 경력

  • 1993.3-1994.2 세브란스병원 인턴
    1998.3-2002.2 세브란스병원 전공의(내과)
    2002.3-2004.2 연세대학교 의과대학 내과학교실 연구강사
    2004.3-2006.2 연세대학교 의과대학 내과학교실 전임강사
    2006.3-2009.2 연세대학교 의과대학 내과학교실 조교수
    2009.3-2015.2 연세대학교 의과대학 내과학교실 부교수
    2011.9-2013.8 미국 국립암센터 연수(MD Anerson Cancer Center)
    2015.3-현 재 연세대학교 의과대학 내과학교실 교수
    2017.3-현 재 연세암병원 종양내과 과장

기타 학술 관련 경력

  • 대한내과학회
    한국임상암학회 이사
    한국유방암학회 진료권고안위원회 위원장
    대한항암요법연구회 홍보위원장
    대한암학회 이사
    미국암연구학회(AACR) 정회원
    미국암학회(ASCO) 정회원
     
    [수상경력]
    2004 Merit Award in 2004 ASCO annual meeting
    2014 보령학술최우수상, 한국임상암학회
    2014 최우수연구상(지성학술상), 연세대학교의과대학 내과학교실

연구,관심분야

  • 유방암의 항암약물치료, 신약임상시험 및 중개연구, Genomics & Liquid Biopsy

강의분야

  • 유방암의 항암약물치료, 신약임상시험 및 중개연구, Genomics & Liquid Biopsy

논문

  • CD44/CD24 and aldehyed dehydrogenase 1 in estrogen receptor-positiveearly breast cancer treated with tamoxifen: CD24 positivity is a poor prognosticator Yong Wha Moon, Hee-Jung An, Ja Seung Koo, Gun Min Kim, Hyunju Han, Seho Park, Seung Il Kim, Hyung Seok Park, Sewha Kim, Seung Ki Kim, Seung Ah Lee, Sohyun Hwang, Gun Woo Son, Joohyuk Sohn. Oncotarget 2017. December 21, 2017.
  • Meeting Highlights: The Second Consensus Conference for Breast Cancer Treatment in Korea Seeyoun Lee, In Hae Park, Seho Park, Joohyuk Sohn, Joon Jeong, Sung Gwe Ahn, Ik Jae Lee, Hae Kyung Lee, Seung Ah Lee, Won Park, Kyung-Hun Lee, Sung-Won Kim, Sang-Ah Han, Kyung Hae Jung, Byung Ho Son. JOURNAL OF BREAST CANCER 20(3) : 228p ~ 233p. Sep 2017.
  • Comparison of standardized uptake value of 18F-FDG-PET-CT with 21-gene recurrence score in estrogen receptor-positive, HER2-negative breast cancer Sung Gwe Ahn, Jae-Hoon Lee, Hak Woo Lee, Tae Joo Jeon, Young Hoon Ryu, Kun Min Kim, Joohyuk Sohn, Mijin Yun, Seung Ah Lee, Joon Jeong, Seung Il Kim. PLOS ONE 12(4): e0175048p ~ p. April 18 2017.
  • The Benefit of Pro Re Nata Antiemetics Provided With Guideline-Consistent Antiemetics in Delayed Nausea Control Sun Young Rha, Joohyuk Sohn, Gun Min Kim, Hye Ryun Kim, Jiyeon Lee. CANCER NURSING epub:p ~ p. April 2017.
  • Chemotherapy-induced irreversible alopecia in early breast cancer patients Gun Min Kim, Sanghwa Kim, Hyung Seok Park, Jee Ye Kim, Sanggen Nam, Seho Park, Seung Il Kim, DoYoung Kim, Joohyuk Sohn. Breast Cancer Res Treat (2017) 163:527?533. 21 March 2017 (Corresponding author)
  • Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer Hyung Soon Park, Joohyuk Sohn, Seung Il Kim, Seho Park, Seul Ghi Gho, Hyun Cheol Chung, Soonmyung Paik, Gun Min Kim. Breast Cancer Res Treat (2017) 163:255?262. 27 February 2017.
  • Detection of Circulating Tumor Cells in Breast Cancer Patients Using Cytokeratin-19 Real-Time RT-PCR Hyung Seok Park, Hyun Ju Han, Soohyeon Lee, Gun Min Kim, Seho Park, Yeon A Choi, Jeong Dong Lee, Gi Moon Kim, Joohyuk Sohn, Seung Il Kim. YONSEI MEDICAL JOURNAL 58(1) : 19-26. 2017 Jan.
  • An Open-Label, Randomized, Parallel, PhaseⅢ Trial Evaluating the Efficacy and Safety of Polymeric Micelle-Formulated Paclitaxel Compared to Conventional Cremophor EL-Based Paclitaxel for Recurrent or Metastatic HER2-Negative Breast Cancer In Hae Park, Joo hyuk Sohn, Sung Bae Kim, Keun Seok Lee, Joo Seop Chung, Soo Hyeon Lee, Tae You Kim, Kyung Hae Jung, Eun Kyung Cho, Yang Soo Kim, Hong Suk Song, Jae Hong Seo, Hun Mo Ryoo, Sun Ah Lee, So Young Yoon, Chul Soo Kim, Yong Tai Kim, Si Young Kim, Mi Ryung Jin, Jungsil Ro. CANCER RESEARCH AND TREATMENT 49 : 569-577. 2016 Sep 12.
  • Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: A propensity score-matched cohort study Namki Hong, Han Gyul Yoon, Da Hea Seo, Seho Park, Seung Il Kim, Joo Hyuk Sohn, Yumie Rhee. EUROPEAN JOURNAL OF CANCER 82:103p ~ 114p. May 2017.
  • The Association between EGFR and cMET Expression and Phosphorylation and Its Prognostic Implication in Patients with Breast Cancer. Young Kwang Chae, Debora de Melo Gagliato, Sachin Gopalkrishna Pai, Benedito Carneiro, Nisha Mohindra, Francis Joseph Giles, Praveen Ramakrishnan-Geethakumari, Joohyuk Sohn, Shuying Liu, Huiqin Chen, Naoto Ueno, Gabriel Hortobagyi, Ana Maria Gonzalez-Angulo. PLoS One. 2016 Apr 7;11(4)
  • Magnetic Resonance Imaging after Completion of Neoadjuvant Chemotherapy Can Accurately Discriminate between No Residual Carcinoma and Residual Ductal Carcinoma In Situ in Patients with Triple-Negative Breast Cancer Park S, Yoon JH, Sohn J, Park HS, Moon HJ, Kim MJ, Kim EK, Kim SI, Park BW. PLoS One 11;11(2):e0149347 . 2016 Feb.
  • Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel: A Multicenter Retrospective Cohort Study. Se Hyun Kim, Kyung Hae Jung, Tae-Yong Kim, Seock-Ah Im, In Sil Choi, Yee Soo Chae, Sun Kyung Baek, Seok Yun Kang, Sarah Park, In Hae Park, Keun Seok Lee, Yoon Ji Choi, Soohyeon Lee, Joo Hyuk Sohn, Yeon-Hee Park, Young-Hyuck Im, Jin-Hee Ahn, Sung-Bae Kim, Jee Hyun Kim. Cancer Research and Treatment 2016; [Epub ahead of print]
  • Do Recent Advances in Diagnostic and Therapeutic Procedures Negate the Benefit of Postmastectomy Radiotherapy in N1 Patients With a Low Risk of Locoregional Recurrence? Chang JS, Lee J, Kim KH, Sohn JH, Kim SI, Park BW, Chung HC, Keum KC, Suh CO, Kim YB Medicine (Baltimore). 2015 Aug;94(33):e1259.
  • Anaplastic Lymphoma Kinase Gene Copy Number Gain in Inflammatory Breast Cancer (IBC): Prevalence, Clinicopathologic Features and Prognostic Implication. Kim MH, Lee S, Koo JS2, Jung KH, Park IH, Jeong J, Kim SI, Park S, Park HS, Park BW, Kim JH, Sohn J PLoS One. 2015 Mar 24;10(3):e0120320. (Corresponding author)
  • Detection of circulating tumor cell-specific markers in breast cancer patients using the quantitative RT-PCR assay. Wang HY, Ahn S, Kim S, Park S, Jung D, Park S, Han H, Sohn J, Kim S, Lee H. Int J Clin Oncol. 2015 Feb 24. [Epub ahead of print]
  • Prediction of short- and longterm survivial for advanced cancer patients after ICU admission. Heo SJ, Kim G, Lee CK, Chung KS, Choi HJ, Sohn J, Lee S. Support Care Cancer. 2014 Nov 23. [Epub ahead of print]
  • cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer. Joohyuk Sohn, Shuying Liu, Napa Parinyanitikul, Jangsoon Lee, Gabriel N. Hortobagyi, Gordon B. Mills, Naoto T. Ueno, Ana M. Gonzalez-Angulo. Journal of Cancer 2014 Oct; 5(9): 745-753 (First author)
  • Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer. Welslau M1, Dieras V, Sohn JH, Hurvitz SA, Lalla D, Fang L, Althaus B, Guardino E, Miles D. Cancer 2014 Mar 1;120 (5):642-51
  • S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial. Moon YW, Lee S, Park BW, Kim EK, Kim SI, Koo JS, Park S, Kim MJ, Chung HC, Kim JH, Sohn J. BMC Cancer 2013 Dec 6;13:583 (Corresponding author)
  • Prolonged clinical benefit from the maintenance hormone therapy in patients with metastatic breast cancer. Lim S1, Lee S, Han J, Park BW, Kim S, Park S, Kim JH, Choi HJ, Sohn J. Breast 2013 Dec;22(6):1205-9 (Corresponding author)
  • Functional proteomics characterization of residual triple-negative breast cancer after standard neoadjuvant chemotherapy. Sohn J, Do KA, Liu S, Chen H, Mills GB, Hortobagyi GN, Meric-Bernstam F, Gonzalez-Angulo AM, Ann Oncol. 2013 Aug;24:2522-6 (First author)
  • Multicentre phase II trial of bevacizumab combined with docetaxel-carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905). Kim HR, Jung KH, Im SA, Im YH, Kang SY, Park KH, Lee S, Kim SB, Lee KH, Ahn JS, Kim SI, Sohn JH. Ann Oncol. 2013 Jun;24(6) Epub 2013 Feb 4. (Corresponding author)
  • Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02. Park YH, Jung KH, Im SA, Sohn JH, Ro J, Ahn JH, Kim SB, Nam BH, Oh do Y, Han SW, Lee S, Park IH, Lee KS, Kim JH, Kang SY, Lee MH, Park HS, Ahn JS, Im YH. J Clin Oncol. 2013 May 10;31(14):1732-9.
  • Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors. Kim HS, Shin SJ, Kim SC, An S, Rha SY, Ahn JB, Cho BC, Choi HJ, Sohn JH, Kim HS, Chung HC, Kim JH, Roh JK, Lee S. Support Care Cancer. 2013 Jun;21(6) Epub 2013 Jan 23
  • A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer. Park KH1, Sohn JH, Lee S, Park JH, Kang SY, Kim HY, Park IH, Park YH, Im YH, Lee HJ, Hong DS, Park S, Shin SH, Kwon HC, Seo JH. Invest New Drugs. 2013 Oct;31(5):1300-6
  • Overexpression of Class III Beta Tubulin and Amplified HER2 Gene Predict Good Response to Paclitaxel and Trastuzumab Therapy. Jung M, Koo JS, Moon YW, Park BW, Kim SI, Park S, Lee SH, Hong S, Rha SY, Chung HC, Kim JH, Sohn J. PLoS One. 2012;7(9):e45127 Epub 2012 Sep 20. (Corresponding author)
  • Prediction of outcomes for patients with brain parenchymal metastases from breast cancer (BC): a new BC-specific prognostic model and a nomogram. Ahn HK, Lee S, Park YH, Sohn JH, Jo JC, Ahn JH, Jung KH, Park S, Cho EY, Lee JI, Park W, Choi DH, Huh SJ, Ahn JS, Kim SB, Im YH. Neuro Oncol. 2012 Jun 11. [Epub ahead of print]
  • Metaplastic breast cancer: clinicopathological features and its prognosis. Lee H, Jung SY, Ro JY, Kwon Y, Sohn JH, Park IH, Lee KS, Lee S, Kim SW, Kang HS, Ko KL, Ro J. J Clin Pathol. 2012 May;65(5):441-6. Epub 2012 Mar 12.
  • Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival. Yap YS1, Cornelio GH, Devi BC, Khorprasert C, Kim SB, Kim TY, Lee SC, Park YH, Sohn JH, Sutandyo N, Wong DW, Kobayashi M, Landis SH, Yeoh EM, Moon H, Ro J. Br J Cancer 2012 Sep 25;107(7):1075-82
  • Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gomez H, Dinh P, Fauria K, Van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horvath Z, Coccia-Portugal M, Domont J, Tseng LM, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, Pusztai L, Untch M, Gelber RD, Piccart-Gebhart M; NeoALTTO Study Team. Lancet. 2012 Feb 18;379(9816):633-40. Epub 2012 Jan 17. Erratum in: Lancet. 2012 Feb 18;379(9816):616. Dosage error in published abstract; MEDLINE/PubMed abstract corrected.
  • Clinical significance of progesterone receptor and HER2 status in estrogen receptor-positive, operable breast cancer with adjuvant tamoxifen. Moon YW, Park S, Sohn JH, Kang DR, Koo JS, Park HS, Chung HC, Park BW J Cancer Res Clin Oncol. 2011 Jul;137(7):1123-30. Epub 2011 Feb 16.
  • Active targeting and safety profile of PEG-modified adenovirus conjugated with herceptin. Kim PH, Sohn JH, Choi JW, Jung Y, Kim SW, Haam S, Yun CO. Biomaterials. 2011 Mar; 32(9):2314-26 (Co-first author)
  • Continuous separation of breast cancer cells from blood samples using multi-orifice flow fractionation(MOFF) and dielectrophoresis(DEP) Hui-Sung Moon, Kiho Kwon, Hyunju Han, Joohyuk Sohn, Seung-Il Kim, Soohyeon Lee, and Hyo-Il Jung Lab Chip. 2011 Mar 21;11(6):1118-25. Epub 2011 Feb 7
  • Molecular subtypes and tumor response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Kim SI, Sohn J, Koo JS, Park SH, Park HS, Park BW. Oncology. 2010;79(5-6):324-30. Epub 2011 Mar 23.
  • A phase I study of nimotuzumab in combination with radiotherapy in stages IIB-IV non-small cell lung cancer unsuitable for radical therapy: Korean results Choi HJ, Sohn JH, Lee CG, Shim HS, Lee IJ, Yang WI, Kwon JE, Kim SK, Park MS, Lee JH, Kim JH Lung Cancer. 2011 Jan; 71(1):55-9
  • Belotecan for relapsing small-cell lung cancer patients initially treated with an irino tecan-containing chemotherapy: A phase II trial.. Jaeheon Jeong, Byoung Chul Cho, Joo Hyuk Sohn, Hye Jin Choi, Se Hyun Kim , Young Joo Lee, Min Kyu Jung, Sang Joon Shin, Moo-Suk Park, Se Kyu Kim, Joon Chang and Joo Hang Kim. Lung cacner 2010 Oct 70(1)77-81
  • Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance Yong Wha Moon, Joo Hyuk Sohn, Hye Jin Choi, Hyun Chang, Byeong-Woo Park, Seung IL Kim, Seho Park, Ja Seung Koo, Yong Tai Kim, Jae Kyung Roh, Hyun Cheol Chung and Joo-Hang Kim Cancer Chemother pharmacol. 2010 Aug 66(3)425-431 (Corresponding author)
  • Weekly 5-fluorouracil plus cisplatin for concurrent chemoradiotherapy in patients with locally advanced head and neck cancer. Young Joo Lee, Chang Geol Lee, Byoung Chul Cho, Gwi Eon Kim, Hye Jin Choi, Eun Chang Choi, Joo Hyuk Sohn, Joo-Hang Kim. Head Neck 2010 Feb; 32(2):235-43
  • Adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided versus empirical chemotherapy in unresectable non-small cell lung cancer. Yong Wha Moon, Joo Hyuk Sohn, Yong Tai Kim, Hyun Chang, Jae Heon Jeong, Young Joo Lee, Joon Chang, Se Kyu Kim, Min Kyu Jung, Soo Jung Hong, Sung Ho Choi and Joo Hang Kim. Anticancer Res 2009 Oct; 29(10):4243-9
  • US surveillance of regional lymph node recurrence after breast cancer surgery. Moon HJ, Kim MJ, Kim EK, Park BW, Youk JH, Kwak JY, Sohn JH, Kim SI. Radiology.2009 Sep; 252(3):673-81
  • Brain metastases from hepatocellular carcinoma: prognostic factors and outcome: brain metastasis from HCC Hye Jin Choi ,Byung Chul Cho , Joo Hyuk Sohn ,Sang Jun Shin,Se Hyun Kim , Joo Hang Kim ,Nae Choon Yoo J Neurooncol , 2009 Feb;91(3):307-13.
  • Sonographic surveillance for the detection of contralateral metachronous breast cancer in an Asian population. Kim MJ, Kim EK, Kwak JY, Park BW, Kim SI, Sohn J, Oh KK AJR Am J Roentgenol. 2009 Jan; 192(1):221-8
  • Phase II study of transarterial holmium-166-chitosan complex treatment in patients with a single, large hepatocellular carcinoma. Sohn JH, Choi HJ, Lee JT, Lee JD, Kim JH, Moon YM, Park K, Park KB, Kim E, Yoo NC. Oncology, 2009; 76(1):1-9. (First author)
  • Role of sonography in the detection of contralateral metachronous breast cancer in an Asian population Kim MJ, Kim EK, Kwak JY, Park BW, Kim SI, Sohn J, Oh KK. AJR Am J Roentgenol. 2008 Feb;190(2):476-80.
  • Chemoradiotherapy with or without consolidation chemotherapy using cisplatin and 5-fluorouracil in anal squamous cell carcinoma: long-term results in 31 patients. Cho BC, Ahn JB, Seong J, Roh JK, Kim JH, Chung HC, Sohn JH, Kim NK BMC Cancer. 2008 Jan 15; 8:8
  • A single institutional experience of surgically resected thymic epithelial tumors over 10 years: clinical outcomes and clinicopathologic features. Kim BK, Cho BC, Choi HJ, Sohn JH, Park MS, Chang J, Kim SK, Kim DJ, Chung KY, Lee CG, Kim JH, Yoo NC. Oncol Rep. 2008 Jun; 19(6):1525-31
  • Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy. Choi HJ, Cho BC, Shin SJ, Cheon SH, Jung JY, Chang J, Kim SK, Sohn JH, Kim JH Cancer Chemother Pharmacol. 2008 Feb; 61(2):309-13
  • The number of residual metastatic lymph nodes following neoadjuvant chemotherapy predicts survival in patients with stage III NSCLC Kim SH, Cho BC, Choi HJ, Chung KY, Kim DJ, Park MS, Kim SK, Chang J, Shin SJ, Sohn JH, Kim JH. Lung Cancer 2008 Jun; 60(3):393-400
  • Retargeting of adenoviral gene delivery via Herceptin-PEG-adenovirus conjugates to breast cancer cells. Jung Y, Park HJ, Kim PH, Lee J, Hyung W, Yang J, Ko H, Sohn JH, Kim JH, Huh YM, Yun CO, Haam S. J Control Release. 2007 Aug 15
  • Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefi tinib. Cho BC, Im CK, Park MS, Kim SK, Chang J, Park JP, Choi HJ, Kim YJ, Shin SJ, Sohn JH, Kim H, Kim JH J Clin Oncol. 2007 Jun 20; 25(18):2528-33
  • Phase II trial of irinotecan and cisplatin with early concurrent radiotherapy in limited - disease small-cell lung cancer. Joo Hyuk Sohn, Yong Wha Moon, Chang Geol Lee, Gwi Eon Kim, Kyung Young Chung, Joon Chang, Se Kyu Kim, Young Sam Kim, Byoung Wook Choi, Hye Jin Choi , Joo-Hang Kim Cancer 2007: 109(9);1845-1850 (Co-first author)
  • Adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided platinum-based 2-drug chemotherapy for unresectable nonsmall-cell lung cancer. Yong Wha Moon, Sung Ho Choi, Yong Tai Kim, PhD , Joo Hyuk Sohn, Joon Chang, Se Kyu Kim, Moo Suk Park , Kyung Young Chung, Hyoun Ju Lee, Joo-Hang Kim. Cancer 2007: 109(9); 1829-1835
  • Multi-disciplinary treatment of a rare pelvic cavity ependymoma. Hwang HJ, Sohn JH, Han SJ, Kim TS, Lee YS, Kim JH Yonsei Med J. 2007 Aug 31; 48(4):719-22 (Corresponding author)
  • A phase II trial of fractionated irinotecan plus carboplatin for previously untreated extensive-disease small cell lung cancer Joo Hyuk Sohn, Hyejin Choi, Jun Chang, Sekyu Kim, Changul Lee, Kyungyoung Chung, Daejun Kim, Byungchul Cho, Sangjun Shin, Yongwha Moon, Joohang Kim, Lung Cancer 2006, 54(3); 365-370 (Co-first author)
  • Paclitaxel and leucovorin-modulated infusional 5-fluorouracil combination chemother apy for metastatic gastric cancer. Byungchuk Cho, Joohang Kim, CB Kim, Joo Hyuk Sohn, YC Lee, JB Ahn Oncology Report 2006;15(3); 621-627
  • Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect. Kyungjoo Choi, Joohang Kim, Youngsook Lee, J Kim, BS Suh, K Suh, S Cho, Joo Hyuk Sohn, GE Kim, Chae-Ok Yun GENE THERAPY 2006; 13(13); 1010-1020
  • Markedly Enhanced Cytolysis by E1B-19kD-Deleted Oncolytic Adenovirus in Combination with Cisplatin A-Rum Yoon, Joo Hang Kim, Young Sook Lee, Hoguen Kim, Ji Young Yoo, Joo Hyuk Sohn, Byeong Woo Park, Chae Ok Yun HUMAN GENE THERAPY 2006; Apr 17:379-390
  • A Pilot Study of Trans-arterial Injection of 166 Holmium-Chotosan Complex for Treatment of Small Hepatocellular Carcinoma. Byoung Chul Cho, Eun Hee Kim, Hye Jin Choi, Joo Hang Kim, Jae Kyung Roh, Hyun Cheol Chung, Joong Bae Ahn, Jong Doo Lee, Jong Tae Lee, Nae Choon Yoo, and Joo Hyuk Sohn Yonsei Medical Journal 2005; 46 (6):799-805 (Corresponding author)
  • Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer. Sun Young Rha, Yong Hwa Moon, Hei Chul Jeung, Yong Tae Kim, Joo Hyuk Sohn, Woo Ick Yang, Chang Ok Suh, Gwi Eon Kim, Jae Kyung Roh, and Hyun Cheol Chung Breast Cancer Research and Treatment 2005; 90: 215-221
  • A Feasibility Study of Adenosine Triphosphate-based Chemotherapy Response Assay (ATP-CRA) as a Chemosensitivity Test for Lung Cancer. Shin Myung Kang, Moo Suk Park, Joon Chang, Se Kyu Kim, Haeryoung Kim, Dong-Hwan Shin, Kyung Young Chung, Dae Joon Kim, Joo Hyuk Sohn, Sung Ho Choi, Jeongmi Kim, Eun Jin Yoon, and Joo-Hang Kim Cancer Research and Treatment 2005; 37 (4):223-227
  • dl-VSVG-LacZ, a VSVG Epitope Incorporated Adenovirus Exhibit Marked Enhance ment in Gene Transduction Efficacy Eun-A Cho, Joo-Hang Kim, Joo Hyuk Sohn, and Chae-Ok Yun HUMAN GENE THERAPY 2003; Nov 20; 14(17):1643-52
  • Increased Cytopathic Effect of Replicating Adenovirus Expressing Adenovirus Death Protein. Eunhee Kim, Joo-Hang Kim, Tae Young Koo, Joo Hyuk Sohn, and Chae-Ok Yun Cancer Research and Treatment 2003; 35(5); 425-432
  • Phase II Study of Gemcitabine and Vinorelbine as Second-Line Chemotherapy in Non small Cell Lung Cancer Yoon Jae Kim, Joo Hyuk Sohn, Chul Kim, Yong Tae Kim, Hai Jin Kim, Joong Bae Ahn, Se Kyu Kim, Joon Chang, Nae Choon Yoo, Joo-Hang Kim, Jae Yong Cho Cancer Research and Treatment 2003; 35(4); 294-298
  • Ad-mTERT-Δ19, a Conditional Replication-Competent Adenovirus Driven by the Hum an Telomerase Promoter, Selectively Replicates in and Elicits Cytopathic Effect in a Cancer Cell-Specific Manner Eunhee Kim, Joo-Hang Kim, Ha-Youn Shin, Han Saem Lee, Jai Myung Yang, Jungho Kim, Joo Hyuk Sohn, Ho Guen Kim, and Chae-Ok Yun. HUMAN GENE THERAPY 2003; 14: 1415-1428
  • Infusional Fluorouracil, Etoposide, and Cisplatin(FEP) in Advanced and Relapsed GastricCancer Joo Hyuk Sohn, Hei Chul Jeung, Hyun Joon Shin, Sun Young Rha, Jae Kyung Roh, Sung Hoon Noh, Jin Sik Min, Byung Soo Kim, Woo Ick Jang, and Hyun Cheol Chung. Am J Clin Oncol 2003; 26(2): 203-209 (First author)
  • Paclitaxel and Cisplatin Combination Chemotherapy in Pretreated Breast Cancer JooHyuk Sohn, Yong Tae Kim, Sun Young Rha, Nae Choon Yu, Jae Kyung Roh, Byung Soo Kim, Chang Ok Suh, Gwi Eon Kim, Woo Ick Jang, and Hyun Cheol Chung. Cancer Research and Treatment 2003; 35(3); 205-211 (First author)
  • Development of a Conditional Replication Competent Adenovirus Controlled by the Human Telomerase Promoter (hTERT) Eunhee Kim, Joo-Hang Kim, Ha-Youn Shin, Han Saem Lee, Joo Hyuk Sohn, Jai Myung Yang, Jungho Kim, and Chae-Ok Yun Cancer Research and Treatment 2003; 35(3); 191-206
  • Infusional 5-Fluorouracil, Leucovorin and Docetaxel in Advanced Gastric Cancer. Yong Tae Kim, Joo Hyuk Sohn, So Hun Kim, Sun Young Rha, Chul Kim, Jae Kyung Roh, Byung Soo Kim, Woo Ick Jang, and Hyun Cheol Chung. Cancer Research and Treatment 2003; 35(2); 123-129
  • A Case of Paraneoplastic Nephrotic Syndrome in a Patient with Ovarian Carcinoma. Yong Tae Kim, Sun Young Rha, Chi Young Shim, Joo Hyuk Sohn, Chul Kim, Nae Choon Yu, Hyun Cheol Chung, Joo Hang Kim, Dae Suk Han, Byung Soo Kim, and Jae Kyung Roh. Yonsei Medical Journal 2003; 44; 539-543
  • A Phase II Study of Topotecan and Etoposide as Second-line Treatment in Chemotherapy-refractory Small-cell Lung Cancer Chul Kim, Joo Hyuk Sohn, Joo Hang Kim, Se Kyu Kim, Young Sam Kim, Joon Chang, and Jae Yong Cho. Cancer Research and Treatment 2002; 34(5); 334-338
  • A Phase II Study of Gemcitabine Monotherapy in Breast Cancer Patients Refractory to Anthracycline and Taxane Jun Yong Park, Chul Kim, Joo Hyuk Sohn, Yong Tae Kim, Sun Young Rha, Woo Ick Jang, Gwi Eon Kim, Hyun Cheol Chung. Cancer Research and Treatment 2002; 34; 274-279
  • A Case of Gigantic Ectasia of Right Coronary Artery Associated with Acute Myocardial Infarction. Jung Rae Cho, Hee Doo Kyung, Sung Jin Oh, Joo Hyuk Sohn, Seunghyun Kwon, Ju Young Yang, and Won Heum Shim. The Korean Circulation Journal 2002; 32(2): 153-158
  • A Case of Subglottic Stenosis in Wegener’s granulomatosis. Young Suck Goo, Hyun Joon Shin, Jae Ho Chung, Hee Doo Kyung, Joo Hyuk Sohn, Seung Hee Choi, Yong-Beom Park, Dong Hwan Shin, and Soo-Kon Lee. The Journal of the Korean Rheumatism Association 2001; 8(02): 128-133
  • A Case of Squamous Cell Carcinoma of Thymus with Negative CD5, Cytokeratin 7 and Positive Cytokeratin 13 Moo Suk Park, Jae Ho Chung, Tae Woong Noh, Joo Hyuk Sohn, Young Sam Kim, Joon Chang, Kyung Young Chung, Joo Hang Kim, Sung Kyu Kim, Dong Hwan Shin, and Se Kyu Kim. Tuberculosis and Respiratory Disease 2001; 51: 281-288
  • Squamous Cell Carcinoma of the Cornea Hyun Joon Shin, Joo Hyuk Sohn, Young Suck Goo, Jeong Youp Park, Chang Hwan Choi, Eung Kweon Kim, Sang-Ho Cho, Nae-Choon Yoo, and Jae Kyung Rho. Yonsei Medical Journal 2001; 42; 576-579
  • Efficacy of Pre- and Postoperative Chemotherapy in Patients with Osteosarcoma of the Extremities. Joo Hyuk Sohn, Sun Young Rha, Hei Cheul Jeung, Hyun Joon Shin, Young Suck Goo, Hyun Cheol Chung, Woo Ick Yang, Soo Bong Hahn, Kyu Ho Shin, Jin Sik Min, Byung Soo Kim, Woo Ick Jang, and Jae Kyung Roh. Cancer Research and Treatment 2001; 33; 520-526 (First author)
  • CD5와 Cytokeratin 7에 음성이고 Cytokeratin 13에 양성인 흉선 편평상피세포암 1예
    결핵 및 호흡기질환(Tuberculosis And Respiratory Diseases) 51/3 :281-288,2001
  • Efficacy of Pre - and Postoperative Chemotherapy in Patients with Osteosarcoma of the Extremities
    대한암학회지 33/6 :520-526,2001
  • A Case of Squamous Cell Carcinoma of Thymus with Negative CD5, Cytokeratin 7 and Positive Cytokeratin 13
    Tuberculosis and Respiratory Diseases 51/ :281-288,2001
  • A Case of Subglottic Stenosis in Wegener’s granulomatosis
    대한류마티스학회지(J Korean Rheum Assoc) 8/2 :128-133,2001
  • Squamous Cell Carcinoma of the Cornea
    YONSEI MEDICAL JOURNAL 42/ :576-579,2001
  • Efficacy of Pre- and Postoperative Chemotherapy in Patients with Osteosarcoma of the Extremities
    Cancer Research and Treatment 33/6 :520-526,2001
  • A Phase II Study of Topotecan and Etoposide as Second-line Treatment in Chemotherapy-refractory Small-cell Lung Cancer
    CANCER RESEARCH AND TREATMENT 34/5 :334-338,2002
  • dl-VSVG-LacZ, a VSV-G epitope incorporated adenoviurs exhibit marked enhancement in gene transduction efficiency
    HUMAN GENE THERAPY 14/7 :1643-1652,2003
  • Infusional 5-flurouracil, leucovorin and docetaxel in advanced gastric cancer
    CANCER RESEARCH AND TREATMENT 35/0 :123-129,2003
  • Phase II Study of Gemcitabine and Vinorelbine as Second-Line Chemotherapy in Non-small Cell Lung Cancer
    CANCER RESEARCH AND TREATMENT 35/4 :294-298,2003
  • Development of a Conditional Replication Competent Adenovirus, Controlled by the Human Telomerase Promoter
    CANCER RESEARCH AND TREATMENT 35/3 :191-206,2003
  • Infusional Fluorouracil, Etoposide, and Cisplatin(FEP) in Advanced and Relapsed Gastric Cancer
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS 26/2 :203-209,2003
  • Paclitaxel and Cisplatin Combination Chemotherapy in Pretreated Breast Cancer
    CANCER RESEARCH AND TREATMENT 35/3 :205-211,2003
  • Increased Cytopathic Effect of Replicating Adenovirus Expressing Adenovirus Death Protein
    CANCER RESEARCH AND TREATMENT 35/5 :425-432,2003
  • A case of paraneoplastic nephrotic syndrome in a patient with ovarian carcinoma
    YONSEI MEDICAL JOURNAL 44/3 :539-543,2003
  • Ad-mTERT-Δ19, a Conditional Replication-Competent Adenovirus Driven by the Human Telomerase Promoter, Selectively Replicates in and Elicits Cytopathic Effect in a Cancer Cell-Specific Manner
    HUMAN GENE THERAPY 14/ :1415-1427,2003
  • E1A/E1B 이중변이형 종양 선택적 살상 아데노바이러스의 개선된 암세포 살상 효과 및 항종양 효과
    JOURNAL OF BACTERIOLOGY AND VIROLOGY 35/2 :113-124,2005
  • Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer
    BREAST CANCER RESEARCH AND TREATMENT 90/3 :215-221,2005
  • A carcinoembryonic antigen-secreting adenocarcinoma arising in tailgut cyst: Clinical implications of carcinoembryonic antigen
    YONSEI MEDICAL JOURNAL 46/4 :555-561,2005
  • A Feasibility Study of Adenosine Triphosphate-based Chemotherapy Response Assay (ATP-CRA) as a Chemosensitivity Test for Lung Cancer
    CANCER RESEARCH AND TREATMENT 37/4 :223-227,2005
  • A pilot study of trans-arterial injection of 166Holmium-Chitosan complex for treatment of small hepatocellular carcinoma
    YONSEI MEDICAL JOURNAL 46/6 :799-805,2005
  • Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect
    GENE THERAPY 13/13 :1010-1020,2006
  • Markedly enhanced cytolysis by E1B-19kD-deleted oncolytic adenovirus in combination with cisplatin
    HUMAN GENE THERAPY 17/4 :379-390,2006
  • 난소에 발생한 간양 암종 1예
    대한부인종양,콜포스코피학회 17,1/ :84-88,2006
  • Paclitaxel and leucovorin-modulated infusional 5-fluorouracil combination chemotherapy for metastatic gastric cancer.
    ONCOLOGY REPORTS 15/ :621-627,2006
  • A phase II trial of fractionated irinotecan plus carboplatin for previously untreated extensive-disease small cell lung cancer
    LUNG CANCER 54/ :365-370,2006
  • Adenosine Tiphosphate-based Chemotherapy Response Assay (ATP-CRA)-guided platinum-based 2-drug chemotherapy for unresectable nonsmall-cell lung cancer
    CANCER 109/9 :1829-1835,2007
  • Phase II trial of irinotecan and cisplatin with early concurrent radiotherapy in limited-disease small-cell lung cancer
    CANCER 109/9 :1845-1850,2007
  • Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib
    JOURNAL OF CLINICAL ONCOLOGY 25/18 :2528-2533,2007
  • Multi-disciplinary treatment of a rare pelvic cavity ependymoma
    YONSEI MEDICAL JOURNAL 48/4 :719-722,2007
  • Retargeting of adenoviral gene delivery via Herceptin-PEG-adenovirus conjugates to breast cancer cells
    JOURNAL OF CONTROLLED RELEASE 123/2 :164-171,2007
  • Role of sonography in the detection of contralateral metachronous breast cancer in an Asian population
    American Journal Of Roentgenology 190/ :476-480,2008
  • Chemoradiotherapy with or without consolidation chemotherapy using cisplatin and 5-fluorouracil in anal squamous cell carcinoma: Long-term results in 31 patients
    Bmc Cancer 8/ :-,2008
  • A single institutional experience of surgically resected thymic epithelial tumors over 10 years - Clinical outcomes and clinicopathologic features
    Oncology Reports 19/ :1525-1531,2008
  • Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy
    Cancer Chemotherapy And Pharmacology 61/ :309-313,2008
  • The number of residual metastatic lymph nodes following neoadjuvant chemotherapy predicts survival in patients with stage III NSCLC
    Lung Cancer 60/3 :393-400,2008
  • Sonographic Surveillance for the Detection of Contralateral Metachronous Breast Cancer in an Asian Population
    AMERICAN JOURNAL OF ROENTGENOLOGY 192/1 :221-228,2009
  • Phase II Study of Transarterial Holmium-166-Chitosan Complex Treatment in Patients with a Single, Large Hepatocellular Carcinoma
    Oncology 76/1 :1-9,2009
  • US surveillance of regional lymph node recurrence after breast cancer surgery
    Radiology 252/3 :673-681,2009
  • Adenosine Triphosphate-based Chemotherapy Response Assay (ATP-CRA)-guided versus Empirical Chemotherapy in Unresectable Non-small Cell Lung Cancer
    Anticancer Research 29/10 :4243-4249,2009
  • Brain metastases from hepatocellular carcinoma: prognostic factors and outcome
    Journal Of Neuro-Oncology 91/3 :307-313,2009
  • Weekly 5-fluorouracil plus cisplatin for concurrent chemoradiotherapy in patients with locally advanced head and neck cancer
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK 32/2 :235-243,2010
  • Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance
    CANCER CHEMOTHERAPY AND PHARMACOLOGY 66/3 :425-431,2010
  • Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: A phase II trial
    Lung Cancer 70/1 :77-81,2010
  • Continuous separation of breast cancer cells from blood samples using multi-orifice flow fractionation (MOFF) and dielectrophoresis (DEP)
    Lab on a Chip 11/6 :1118-1125,2011
  • A phase I study of nimotuzumab in combination with radiotherapy in stages IIB-IV non-small cell lung cancer unsuitable for radical therapy: Korean results
    LUNG CANCER 71/1 :55-59,2011
  • Molecular Subtypes and Tumor Response to Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer
    ONCOLOGY 79/5-6 :324-330,2011
  • Clinical significance of progesterone receptor and HER2 status in estrogen receptor-positive, operable breast cancer with adjuvant tamoxifen
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY 137/7 :1123-1130,2011
  • Active targeting and safety profile of PEG-modified adenovirus conjugated with herceptin
    BIOMATERIALS 32/9 :2314-2326,2011
  • Overexpression of Class III Beta Tubulin and Amplified HER2 Gene Predict Good Response to Paclitaxel and Trastuzumab Therapy.
    PLOS ONE 7/9 :e45127-e45127,2012
  • Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
    LANCET 379/9816 :633-640,2012
  • Prediction of outcomes for patients with brain parenchymal metastases from breast cancer (BC): a new BC-specific prognostic model and a nomogram
    NEURO-ONCOLOGY 14/8 :1105-1113,2012
  • Metaplastic breast cancer: clinicopathological features and its prognosis
    JOURNAL OF CLINICAL PATHOLOGY 65/5 :441-446,2012
  • Multicentre phase II trial of bevacizumab combined with docetaxel?-carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905)
    ANNALS OF ONCOLOGY 24/6 :1485-1490,2013
  • Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors
    SUPPORTIVE CARE IN CANCER 21/6 :1751-1759,2013
  • Functional proteomics characterization of residual triple-negative breast cancer after standard neoadjuvant chemotherapy.
    ANNALS OF ONCOLOGY 24/10 :2522-2526,2013
  • S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: Phase II trial
    BMC CANCER 13/583 :1-7,2013
  • Prolonged clinical benefit from the maintenance hormone therapy in patients with metastatic breast cancer
    BREAST 22/6 :1205-1209,2013
  • A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer
    INVESTIGATIONAL NEW DRUGS 31/5 :1300-1306,2013
  • Patient-Reported Outcomes From EMILIA, a Randomized Phase 3 Study of Trastuzumab Emtansine (T-DM1) Versus Capecitabine and Lapatinib in Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Breast Cancer
    CANCER 120/5 :642-651,2014
  • cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer
    JOURNAL OF CANCER 5/9 :745-753,2014
  • Anaplastic lymphoma kinase gene copy number gain in inflammatory breast cancer (IBC): Prevalence, clinicopathologic features and prognostic implication
    PLOS ONE 10/3 :e0120320-,2015
  • 성장인자수용체-2 양성 유방암 조직에서 표적치료 전후의 성장인자수용체군 발현양상
    Korean Journal of clinical oncology (대한임상종양학회지) 11/1 :12-19,2015
  • Do Recent Advances in Diagnostic and Therapeutic Procedures Negate the Benefit of Postmastectomy Radiotherapy in N1 Patients With a Low Risk of Locoregional Recurrence?
    MEDICINE 94/33 :1-9,2015
  • Prediction of short- and long-term survival for advanced cancer patients after ICU admission
    SUPPORTIVE CARE IN CANCER 23/6 :1647-1655,2015
  • Detection of circulating tumor cell-specific markers in breast cancer patients using the quantitative RT-PCR assay
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY 20/5 :878-890,2015
  • Magnetic Resonance Imaging after Completion of Neoadjuvant Chemotherapy Can Accurately Discriminate between No Residual Carcinoma and Residual Ductal Carcinoma In Situ in Patients with Triple-Negative Breast Cancer
    PLOS ONE 11/2 :e0149347-,2016
  • Epithelial-to-mesenchymal transition leads to loss of EpCAM and different physical properties in circulating tumor cells from metastatic breast cancer
    ONCOTARGET 7/17 :24677-24687,2016
  • The Association between EGFR and cMET Expression and Phosphorylation and Its Prognostic Implication in Patients with Breast Cancer
    PLOS ONE 11/4 :e0152585-,2016
  • Incidence of Febrile Neutropenia in Korean Female Breast Cancer Patients Receiving Preoperative or Postoperative Doxorubicin/Cyclophosphamide Followed by Docetaxel Chemotherapy
    JOURNAL OF BREAST CANCER 19/1 :76-82,2016
  • Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel in Breast Cancer: A Multicenter Retrospective Cohort Study
    CANCER RESEARCH AND TREATMENT 48/4 :1,373-1,381,2016
  • Detection of Circulating Tumor Cells in Breast Cancer Patients Using Cytokeratin-19 Real-Time RT-PCR
    YONSEI MEDICAL JOURNAL 58/1 :19-26,2017
  • Comparison of standardized uptake value of 18F-FDG-PET-CT with 21-gene recurrence score in estrogen receptor-positive, HER2-negative breast cancer.
    PLOS ONE 12/4 :e0175048-,2017
  • Chemotherapy-induced irreversible alopecia in early breast cancer patients
    BREAST CANCER RESEARCH AND TREATMENT 163/3 :527-533,2017
  • Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer
    BREAST CANCER RESEARCH AND TREATMENT 163/2 :255-262,2017
  • Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: A propensity score-matched cohort study
    EUROPEAN JOURNAL OF CANCER 82/ :103-114,2017
  • Meeting Highlights: The Second Consensus Conference for Breast Cancer Treatment in Korea
    JOURNAL OF BREAST CANCER 20/3 :228-233,2017
  • An Open-label, Randomized, Parallel, Phase III Trial Evaluating the Efficacy and Safety of Polymeric Micelle-Formulated Paclitaxel Compared to Conventional Cremophor EL-Based Paclitaxel for Recurrent or Metastatic HER2-Negative Breast Cancer
    CANCER RESEARCH AND TREATMENT 49/3 :569-577,2017
  • Next-generation sequencing of BRCA1/2 in breast cancer patients: potential effects on clinical decision-making using rapid, high-accuracy genetic results
    ANNALS OF SURGICAL TREATMENT AND RESEARCH 92/5 :331-339,2017
  • CD44/CD24 and aldehyde dehydrogenase 1 in estrogen receptor-positive early breast cancer treated with tamoxifen: CD24 positivity is a poor prognosticator
    ONCOTARGET 9/2 :2,622-2,630,2018
  • The Benefit of Pro Re Nata Antiemetics Provided With Guideline-Consistent Antiemetics in Delayed Nausea Control.
    CANCER NURSING 41/2 :49-57,2018
  • Locoregional Treatment of the Primary Tumor in Patients With De Novo Stage IV Breast Cancer: A Radiation Oncologist's Perspective
    CLINICAL BREAST CANCER 18/2 :167-178,2018
  • Feasibility of Charcoal Tattooing of Cytology-Proven Metastatic Axillary Lymph Node at Diagnosis and Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Breast Cancer Patients
    CANCER RESEARCH AND TREATMENT 50/3 :801-812,2018
  • Ramucirumab Safety in East Asian Patients: A Meta-Analysis of Six Global, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trials.
    Journal of Global Oncology 4/ :1-12,2018
  • External validation of IBTR! 2.0 nomogram for prediction of ipsilateral breast tumor recurrence
    Radiation Oncology Journal 36/2 :139-146,2018
  • A Phase II Study to Evaluate the Safety and Efficacy of Pegteograstim in Korean Breast Cancer Patients Receiving Dose-Dense Doxorubicin/Cyclophosphamide.
    CANCER RESEARCH AND TREATMENT 51/2 :812-818,2019
  • Effect of primary tumor resection on overall survival in patients with stage IV breast cancer.
    BREAST JOURNAL 25/5 :908-915,2019
  • Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01)
    CANCER RESEARCH AND TREATMENT 51/1 :43-52,2019

손주혁

콘텐츠 처음으로 이동

네크워크 링크안내/사이트 정보